AI Blog

Artificial Intelligence – Advancing the Pharmaceutical and Medical Device Industries

View on LinkedIn

Join the LinkedIn AI group!

Considering Bias Without Bias

Considering Bias Without Bias

on 29 November, 2021

By Bill Whitford (DPS Group), Betsy Macht (Johnson & Johnson, retired), and Toni Manzano (Aizon)…

Data Governance: An AI in Pharma Requirement

Data Governance: An AI in Pharma Requirement

on 20 November, 2021

By Toni Manzano (Aizon), Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group) and …

Modeling RNA Virus and Vaccine Structure

Modeling RNA Virus and Vaccine Structure

on 27 September, 2021

By William Whitford (DPS Group) Purpose: AI has applications throughout the value chain, and he…

In Their Own Words: Participants Review the AI Summit

In Their Own Words: Participants Review the AI Summit

on 1 August, 2021

By Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group), and AIO Team Healthcare P…

AI in Pharma Adoption, Part 5: AI Value in Complex, Unstructured and Multiparametric Data

AI in Pharma Adoption, Part 5: AI Value in Complex, Unstructured and Multiparametric Data

on 29 July, 2021

By Toni Manzano (Aizon), Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group) and …

AI in Pharma Adoption, Part 4: Three Real Use Cases of AI Implementation in Pharma – NOT Science Fiction!

AI in Pharma Adoption, Part 4: Three Real Use Cases of AI Implementation in Pharma – NOT Science Fiction!

on 27 July, 2021

By Toni Manzano (Aizon), Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group) and …

AI in Pharma Adoption, Part 3: AI is Transforming Manufacturing—The Hows and Whys

AI in Pharma Adoption, Part 3: AI is Transforming Manufacturing—The Hows and Whys

on 25 May, 2021

By Toni Manzano (Aizon), Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group) and …

AI in Pharma Adoption, Part 2: “Good AI Begins With Good Data”

AI in Pharma Adoption, Part 2: “Good AI Begins With Good Data”

on 19 April, 2021

By Toni Manzano (Aizon), Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group) and …

AI in Pharma Adoption, Part 1: Why is AI Not Broadly Adopted in the Lifescience Industries (Pharma, Biologics and Medical Devices)?

AI in Pharma Adoption, Part 1: Why is AI Not Broadly Adopted in the Lifescience Industries (Pharma, Biologics and Medical Devices)?

on 1 February, 2021

By Toni Manzano (Aizon), Mario Stassen (Stassen Pharmaconsult BV), and AIO Team The statistical meth…

About the Association of Food and Drug Officials (AFDO)

The Association of Food and Drug Officials (AFDO) is a well-recognized national organization that represents state, territorial, and local regulatory. The Association’s principal purpose is to act as the leader and a resource to state, territorial, and local regulatory agencies in developing strategies to resolve and promote public health and consumer protection related to the regulation of food, medical products, and cosmetics. Visit AFDO at www.afdo.org.

About Regulatory Affairs Professionals Society (RAPS)

The Regulatory Affairs Professionals Society (RAPS) is the largest global organization of professionals involved with regulatory and quality for healthcare products, including medical devices, pharmaceuticals and biologics, diagnostics, and digital health. Founded in 1976 as a neutral, nonprofit organization, RAPS supports and elevates the regulatory profession with education and training, professional standards, publications, research, networking, career development, and other valuable resources. RAPS is home to the Regulatory Affairs Certification (RAC), the only post-academic professional credential to recognize regulatory excellence. The society is headquartered in suburban Washington, D.C., with chapters and affiliates worldwide. www.raps.org.

© 2023 | AFDO / RAPS Healthcare Products Collaborative | Privacy Policy